- Conditions
- Pancreatic Cancer
- Interventions
- fluorouracil, gemcitabine hydrochloride, leucovorin calcium, oxaliplatin, adjuvant therapy, conventional surgery, neoadjuvant therapy, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years to 120 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2014
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
Condition Directory
Pancreatic Cancer clinical trials
Directory of U.S. ClinicalTrials.gov public records for Pancreatic Cancer. Browse Pancreatic Cancer recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.
By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 17, 2026 Report an issue
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
1135
Shown on this page
12
Current sort
Recently updated
Condition scope
Pancreatic Cancer
Additional filters apply within this condition.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
How Pancreatic Cancer studies are organized in the registry
Most pancreatic cancer records use the formal phrase “pancreatic ductal adenocarcinoma” or the abbreviation PDAC somewhere in the listing, and studies commonly separate resectable, locally advanced, and metastatic settings in their titles. The overall volume is smaller than for other major cancers, so a single well-chosen term usually narrows the list enough.
Terms that often appear in related listings
These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.
Showing 577–588 of 1,135 matching trials for Pancreatic Cancer.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Non Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Head and Neck Cancer, GastroEsophageal Cancer
- Interventions
- FT536, Cyclophosphamide, Fludarabine, IL-2, Avelumab, Pembrolizumab, Nivolumab, Atezolizumab, Trastuzumab, Cetuximab, Amivantamab
- Drug · Combination Product
- Lead sponsor
- Fate Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 5
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Hackensack, New Jersey + 2 more
- Conditions
- Prostate Carcinoma, Breast Neoplasm, Pancreatic Cancer, BRCA1 Mutation, BRCA2 Mutation
- Interventions
- Web-based Counseling, Standard Care
- Behavioral
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 25 Years to 70 Years · Male only
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Germline BRCA1/2 Mutations and, Metastatic Adenocarcinoma of the Pancreas
- Interventions
- Olaparib, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2023
- U.S. locations
- 20
- States / cities
- Gilbert, Arizona • Orange, California • Stanford, California + 14 more
- Conditions
- Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor, Shared Neoantigen-Positive Solid Tumors
- Interventions
- GRT-C903, GRT-R904, nivolumab, ipilimumab
- Biological
- Lead sponsor
- Gritstone bio, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Santa Monica, California • Jacksonville, Florida + 8 more
- Conditions
- Pancreatic Cancer
- Interventions
- medical chart review, questionnaire administration, study of socioeconomic and demographic variables, biopsy
- Other · Procedure
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years to 100 Years
- Enrollment
- 379 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2013
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Pancreatic Cancer
- Interventions
- gemcitabine hydrochloride, imatinib mesylate
- Drug
- Lead sponsor
- University of Medicine and Dentistry of New Jersey
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 8
- States / cities
- Chicago, Illinois • Freehold, New Jersey • Hamilton, New Jersey + 3 more
- Conditions
- Neoplasms, Colorectal Neoplasms, Melanoma, Pancreatic Neoplasms, Sarcoma, Ovarian Neoplasms, Brain Neoplasms, Thyroid Neoplasms, Neuroendocrine Tumors, Cholangiocarcinoma, Salivary Gland Neoplasms, Head and Neck Neoplasms, Thyroid Cancer, Papillary, Lymphoma, Large-Cell, Anaplastic, Neoplasms by Site, Respiratory Tract Neoplasms, Thoracic Neoplasms, Respiratory Tract Diseases, Carcinoma, Bronchogenic, Bronchial Neoplasms, Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Digestive System Diseases, Gastrointestinal Diseases, Colonic Diseases, Intestinal Diseases, Central Nervous System
- Interventions
- Alectinib
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 29
- States / cities
- Culver City, California • Los Angeles, California • Sacramento, California + 21 more
- Conditions
- HER2-positive Breast Cancer, HER2 Gene Mutation, HER-2 Gene Amplification, HER2 Positive Gastric Cancer, Salivary Gland Cancer, Salivary Gland Tumor, Salivary Gland Carcinoma, Salivary Gland Neoplasms, Lung Cancer, Colo-rectal Cancer, Rare Diseases, Solid Tumor, Recurrent Gastric Cancer, Recurrent Colon Cancer, Recurrent Breast Cancer, Head and Neck Cancer, Head and Neck Carcinoma, Bladder Cancer, Cervical Cancer, Liver Cancer, Bile Duct Cancer, Urologic Cancer, Pancreatic Cancer, Prostate Cancer, Recurrent Prostate Cancer, Rectal Cancer, Recurrent Ovarian Carcinoma, Recurrent Renal Cell Cancer, Rectal Cancer Stage II, Rectal Cancer Stage I, Rectal Cancer Stage III, Skin Cancer, Mouth Cancer, Lip Cancer Stage I, Tongue Cancer, Breast Neoplasm Malignant Primary, Larynx Cancer, Tonsil Cancer, Palate Cancer, Mucoepidermoid Carcinoma, Primary Peritoneal Carcinoma, Mucinous Adenocarcinoma Gastric, Mucinous Breast Cancer Recurrent, Cholangiocarcinoma
- Interventions
- A166
- Drug
- Lead sponsor
- Klus Pharma Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 10
- States / cities
- Sarasota, Florida • Boston, Massachusetts • Detroit, Michigan + 7 more
- Conditions
- Metastatic Pancreatic Adenocarcinoma, Refractory Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
- Interventions
- Nivolumab, Radiation Therapy, TLR9 Agonist SD-101
- Biological · Radiation · Drug
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Metastatic Pancreatic Adenocarcinoma
- Interventions
- Gemcitabine, Taxotere, Xeloda, Cisplatin, Irinotecan
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 76 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Obstructive Jaundice, Pancreatic Cancer
- Interventions
- Metal stent, Plastic stent
- Procedure
- Lead sponsor
- AdventHealth
- Other
- Eligibility
- 19 Years to 85 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2022
- U.S. locations
- 1
- States / cities
- Orlando, Florida
About this Pancreatic Cancer clinical trials directory page
- What this page lists
- U.S. ClinicalTrials.gov public records that list Pancreatic Cancer as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
- How to narrow results
- Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Pancreatic Cancer.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.
Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Pancreatic Cancer.